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CORRESPONDENCE
Incidence of pseudomembranous colitis after
vancomycin-treated MRSA infection
Antibiotic-associated diarrhea (AAD), antibiotic-
associated colitis (AAC) and pseudomembranous
colitis (PMC) are recognized as complications of
antibiotic treatment (with cephalosporins, penicil-
lins, clindamycin and others), especially in elderly
and immunocompromised patients – the groups
most susceptible to Clostridium difﬁcile infection.
C. difﬁcile has been identiﬁed in recent years as a
common nosocomial pathogen [1,2]. Other high-
risk groups have been identiﬁed and include
patients in intensive care units and surgery wards,
and those with cancer or burns [3–5]. However,
the most important risk factor is the use of antibio-
tics. A signiﬁcant association has been described
between the use of vancomycin andmetronidazole
and C. difﬁcile infection [6]. Vancomycin and
some other glycopeptides [7] are very effective
against different Gram-positive bacteria, espe-
cially against C. difﬁcile strains, which are very
susceptible to these antibiotics. However, Hecht
and Olinger described C. difﬁcile colitis secondary
to intravenous vancomycin treatment in 1989
[8]. This situation could be explained by dis-
ruption of the normal intestinal microﬂora or
‘colonization resistance factor’ during antibiotic
treatment [9].
In this communication, we present the incidence
of PMC occurring in a patient after vancomycin-
treated urinary tract infection, caused by a methi-
cillin-resistant Staphylococcus aureus (MRSA).
A 46-year-old man was admitted to hospital for
surgery to a previously diagnosed vascular tumor
of the left cerebral hemisphere. The interview with
the patient revealed hypertension and ischemic
heart disease. The patient was operated on and
the vascular tumor was removed. On day 11 post-
surgery, cerebrospinal meningitis and encephalitis
were diagnosed. At the same time, in relation to an
increasing component of respiratory failure (pCO2
54mmHg, saturation 75–80%), the patient was
transferred to the intensive care unit (ICU), where
he was intubated and ventilated with a respirator
in synchronous intermittent mandatory ventila-
tion (SIMV) mode. Intravenous antibiotic treat-
ment was started with amoxicillin–clavulanate
3 1.2 g and metronidazole 3 0.5 g. In addition,
the patient was given intravenous furosemide
3 10mg, subcutaneous clexane (2 40mg) and
ﬂuids. After 16 days of hospitalization in ICU, the
patient was transferred back to the Neurosurgery
Department in a generally good condition. After
another 7weeks, the patient returned to ICU with
urinary tract infection and another episode of
respiratory failure. This time, the patient did not
require substitute ventilation, but only oxygen sup-
plementation through a facial mask. MRSA was
cultured from the urine. The patient was adminis-
tered intravenous vancomycin 3 500mg. His
temperature was persistently 38–39 8C and there
was leucocytosis in the range 20 000–25 000. After
10 days of vancomycin treatment diarrhea ap-
peared. A high concentration of C. difﬁcile toxins
was determined in stool specimen by Tox A/B-test
(TechLab Co., Blacksburg, VA, USA) [10,11] and
numerous colonies of C. difﬁcile were cultured on
CCCA selective medium. Metronidazole treat-
ment was started immediately. After 2 more days
pulmonary edema appeared and the patient was
intubated and ventilated. In spite of further treat-
ment the patient died the following day.
In vitro susceptibility testing of the C. difﬁcile
strain to vancomycin by Etest (AB biodisk, Solna,
Sweden) demonstrated high sensitivity to vanco-
mycin (MIC¼ 0032mg/L).
We describe here PMC occurring in a patient
with a vancomycin-treated urinary tract infec-
tion caused by MRSA. The use of intravenous
vancomycin was used and probably disrupted
the intestinal ecosystem of the patient, although
it should be noted that the patient had under-
gone surgery and was receiving treatment with
other antibiotics. This patient was hospitalized in
different wards over a long period (more than
2months). Thus a wide spectrum of risk factors
(antibiotic treatment, long-term hospitalization,
surgery), predisposing to C. difﬁcile-associated
infection was present.
The mechanism of PMC [12–14] in this case is
complicated. Initially, it is probable that the pre-
vious antimicrobial treatment played an important
role in disruption of the normal intestinal ﬂora,
‘colonization resistance factor’. Next, vancomycin
was administered intravenously for treatment of
a urinary MRSA infection (not orally, which is
very effective against C. difﬁcile strains). Vancomy-
cin probably caused additional disruption of the
‘colonization resistance factor’, thus promoting
C. difﬁcile multiplication. Relapse of C. difﬁcile-
associated diarrhea has frequently been described
in the literature after vancomycin treatment. Most
investigators believed that these relapses were
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caused by the germination of bacterial spores still
present in the intestine after vancomycin admin-
istration.
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